Clinical Trial Update: Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AFM13 in combination with AB-101 for relapsed or refractory Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma was terminated. Res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• AB-101
• AFM13

Snippet

Sponsor: Affimed GmbH | Conditions: Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-08-20